This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

This study has been completed.
Information provided by (Responsible Party):
Alios Biopharma Inc. Identifier:
First received: March 20, 2014
Last updated: December 22, 2014
Last verified: March 2014
This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.

Condition Intervention Phase
Respiratory Syncytial Virus Infections Drug: ALS-008176 Drug: vehicle Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model

Resource links provided by NLM:

Further study details as provided by Alios Biopharma Inc.:

Primary Outcome Measures:
  • Change in viral load measurements. [ Time Frame: Baseline to day 12 ]

Enrollment: 62
Study Start Date: March 2014
Study Completion Date: July 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ALS-008176
ALS-008176 drug substance for oral suspension
Drug: ALS-008176
Placebo Comparator: vehicle alone
Vehicle alone
Drug: vehicle


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 to 45 years, inclusive.
  • In good health with no history of major medical conditions
  • A total body weight ≥ 50 kg and a body mass index (BMI) of > 18kg/m2.

Exclusion Criteria:

  • Acute or chronic medical illness
  • Positive for Human Immunodeficiency Virus, Hepatitis B or C
  • Nose or nasopharynx abnormalities
  • Abnormal lung function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02094365

United Kingdom
Retroscreen Virology Ltd
London, United Kingdom
Sponsors and Collaborators
Alios Biopharma Inc.
Principal Investigator: Hosnieh Fathi, MD, MSc Retroscreen Virology Ltd.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Alios Biopharma Inc. Identifier: NCT02094365     History of Changes
Other Study ID Numbers: ALS-8176-502
Study First Received: March 20, 2014
Last Updated: December 22, 2014

Additional relevant MeSH terms:
Virus Diseases
Respiratory Syncytial Virus Infections
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections processed this record on June 23, 2017